# Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

> **NCT02555748** · PHASE4 · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 47 (actual)

## Conditions studied

- Metastatic Renal Cell Cancer

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT02555748
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-17
- **Primary completion:** 2020-01-16
- **Final completion:** 2020-01-16
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555748, "Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02555748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*